Biomarker Identification Drives Research and Drug Development in NSCLC and SCLC
Ranee Mehra, MD, and colleagues detail treatment updates across lung cancer subtypes, including navigating the array of available ALK inhibitors in NSCLC.
United States University Of Maryland Samuel Rosner Ranee Mehra University Of Maryland Medical System National Comprehensive Cancer Network
Source: onclive.com